Scinai Immunotherapeutics
Sector: Healthcare & Life Sciences
About Scinai Immunotherapeutics
Scinai Immunotherapeutics (Nasdaq: SCNI) is a biopharmaceutical company with a dual-platform strategy. In 2026, the company expanded its 'Scinai BioServices' CDMO unit with a new sterile fill-and-finish system, while advancing its NanoAb pipeline for mild-to-moderate psoriasis into Phase 1/2a clinical trials.
Products
VHH-Based Antibody Platform: Flexible Formats, Disciplined Validation
Scinai’s VHH-based antibody platform enables the design of compact, high-affinity binding domains that can be deployed across multiple therapeutic formats, including local delivery and systemic antibody constructs. The platform supports selective development of mono-, bi-, and tri-specific antibodies across immune-mediated and inflammatory diseases, with a focus on capital-efficient validation through lead programs. The VHH programs are based on licensed technology from the Max Planck Institute for Multidisciplinary Sciences and University Medical Center Göttingen (Germany). PC111: A First-in-Class Monoclonal Antibody for Severe Dermatologic Diseases Complementing the VHH-based platform, Scinai is advancing PC111, a fully human, first-in-class monoclonal antibody targeting soluble Fas Ligand (sFasL). PC111 is designed to treat severe, high-unmet-need dermatologic conditions, including Pemphigus and Stevens–Johnson syndrome / toxic epidermal necrolysis (SJS/TEN). PC111 is licensed from Pincell S.r.l. (Italy), and is being developed as Scinai’s flagship near-term value driver.